Skip to main content

Table 4 EQ-5D utilities

From: Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

  

UK

France

Spain

Italy

Germany

USA

Total

All RVVC sample, during the day of completion of the questionnaire (a)

 

N

100

107

100

105

106

102

620

(UK TTO formula)

Mean (Sd)

0.74 (0.28)

0.72 (0.25)

0.67 (0.34)

0.61 (0.30)

0.76 (0.25)

0.68 (0.34)

0.70 (0.30)

(country specific formula)

Mean (Sd)

0.74 (0.28)

0.77 (0.23)

0.72 (0.32)

-

0.86 (0.20)

0.76 (0.23)

-

Women with infection, during the day of completion of the questionnaire

 

N

 

5

4

7

7

7

30

(UK TTO formula)

Mean (Sd)

-

0.62 (0.41)

0.48 (0.30)

0.73 (0.10)

0.79 (0.34)

0.53 (0.33)

0.64 (0.31)

(country specific formula)

Mean (Sd)

-

0.78 (0.22)

0.73 (0.33)

-

0.87 (0.20)

0.77 (0.23)

-

Women Without infection, during the day of completion of the questionnaire

 

N

 

102

96

98

99

95

490

(UK TTO formula)

  

0.73 (0.25)

0.68 (0.34)

0.60 (0.31)

0.75 (0.24)

0.69 (0.34)

0.69 (0.30)

(country specific formula)

Mean (Sd)

 

0.78 (0.22)

0.73 (0.33)

-

0.87 (0.20)

0.77 (0.23)

-

General population (b)

 

N

3395

2892

5473

4709

3552

4000

-

 

Mean (Sd)

0.92 (0.22)

0.89 (−)

0.93 (−)

0.90 (−)

0.94 (−)

0.88 (−)

0.91 (−)

 

Adjusted mean (Sd)

-

0.86 (−)

0.89 (−)

0.87 (−)

0.92 (−)

-

-

 

Source

Dennis et al.

König et al.

König et al.

König et al.

König et al.

Kind et al.

-

Difference (a - b)

        

(UK TTO formula)

Mean (Sd)

−0.18 (−)

−0.17 (−)

−0.26 (−)

−0.29 (−)

−0.18 (−)

−0.20 (−)

−0.21 (−)

 

Adjusted mean (Sd)

-

−0.14 (−)

−0.22 (−)

−0.26 (−)

−0.16 (−)

-

-

(country specific formula)

Mean (Sd)

−0.18 (−)

−0.12 (−)

−0.21 (−)

-

−0.08 (−)

−0.12 (−)

-

 

Mean (Sd) (adjusted)

-

−0.09 (−)

−0.17 (−)

-

−0.06 (−)

-

-

During the last acute episode (at the completion of the questionnaire or before) (c)*

 

N

100

107

100

105

106

102

520

(UK TTO formula)

Mean (Sd)

0.71 (0.27)

0.52 (0.33)

0.48 (0.34)

0.42 (0.35)

0.62 (0.28)

0.51 (0.36)

0.51 (0.34)

(country specific formula)

Mean (Sd)

0.71 (0.27)

0.59 (0.31)

0.54 (0.35)

-

0.76 (0.24)

0.64 (0.24)

-

Symptom-free period (at the completion of the questionnaire or before) (d)*

 

N

100

107

100

105

106

102

520

(UK TTO formula)

Mean (Sd)

0.86 (0.24)

0.72 (0.26)

0.68 (0.34)

0.62 (0.31)

0.77 (0.24)

0.69 (0.33)

0.70 (0.30)

(country specific formula)

Mean (Sd)

0.86 (0.24)

0.77 (0.23)

0.73 (0.32)

-

0.87 (0.19)

0.77 (0.23)

-

Difference (c - d)*

 

N

100

107

100

105

106

102

520

Utility score (UK TTO formula)

Mean (Sd)

−0.15 (0.23)

−0.20 (0.29)

−0.20 (0.34)

−0.20 (0.30)

−0.15 (0.23)

−0.18 (0.27)

−0.19 (0.29)

Utility score (country specific formula)

Mean (Sd)

−0.15 (0.23)

−0.19 (0.25)

−0.19 (0.32)

-

−0.12 (0.20)

−0.12 (0.18)

-

  1. *Total do not include data from the UK, as questions about symptoms were formulated differently in the UK version.